Treatment of advanced leukemia in mice with mRNA engineered T cells

• Published in: Human gene therapy Vol. 22; no. 12; p. 1575
• Main Authors: Barrett, David M, Zhao, Yangbing, Liu, Xiaojun, Jiang, Shuguang, Carpenito, Carmine, Kalos, Michael, Carroll, Richard G, June, Carl H, Grupp, Stephan A
• Format: Journal Article
• Language: English
• Published: United States 01.12.2011
• Subjects: Animals; Antigens, CD19 - genetics; Blotting, Western; Cells, Cultured; Cytotoxicity, Immunologic - immunology; Electroporation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; GPI-Linked Proteins - genetics; Humans; Immunotherapy, Adoptive; Lentivirus - genetics; Mice; Mice, Inbred NOD; Mice, SCID; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Real-Time Polymerase Chain Reaction; Receptors, Antigen - genetics; Recombinant Fusion Proteins - genetics; RNA, Messenger - genetics; T-Lymphocytes - metabolism; T-Lymphocytes - transplantation; T-Lymphocytes, Cytotoxic - immunology; Tumor Burden - immunology; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

Cytotoxic T lymphocytes (CTLs) modified with chimeric antigen receptors (CARs) for adoptive immunotherapy of hematologic malignancies are effective in preclinical models and are being tested in several clinical trials. Although CTLs bearing stably expressed CARs generated by integrating viral vector...